Genetics & heredity

Gene Therapy Pioneers Win $3 Million Breakthrough Prize

Is gene therapy being killed by broken economics or accelerated by unstoppable market-driven innovation?

Published APR 20

Gene Therapy Pioneers Win $3 Million Breakthrough Prize

Story

Above: Dr. Albert Maguire and Dr. Jean Bennett at the 12th Breakthrough Prize Ceremony on April 18 in Santa Monica, California. Image credit: Taylor Hill/FilmMagic/Getty Images

The Facts

Jean Bennett, Albert Maguire and Katherine High were awarded the Breakthrough Prize in Life Sciences for developing Luxturna, the first FDA-approved gene therapy for inherited retinal disease. The $3 million prize was presented at a ceremony in Los Angeles on Saturday.
Breakthrough
Pennmedicine
Luxturna treats Leber congenital amaurosis, a genetic disorder caused by mutations in the RPE65 gene that typically leads to total blindness by early adulthood. The therapy delivers a functional copy of the gene into retinal cells using an adeno-associated virus.
Breakthrough
Pennmedicine
The Scientist
Endpoints News
Bennett and Maguire successfully demonstrated the therapy in dogs with RPE65 mutations before advancing to human trials. The couple adopted two of the treated dogs, named Venus and Mercury, during the research process.
NewsBytes
LBC
guardian
Luxturna received FDA approval in 2017 and is priced at $850,000, making it among the most expensive gene therapies in the world. The therapy is currently available in the U.S., Canada, Australia and Switzerland.
The Scientist
LBC
A separate Breakthrough Prize in Life Sciences was awarded to Swee Lay Thein and Stuart Orkin for research that led to Casgevy, the first CRISPR-Cas9 gene-editing therapy, approved for sickle cell disease and beta thalassemia.
Asatu News
guardian
ChosunBiz
Thein identified BCL11A as a gene that regulates fetal hemoglobin production in adults, a finding later used by Orkin's team to develop an approach that disables the gene, prompting cells to produce healthy fetal hemoglobin in place of defective adult hemoglobin.
Inbox
The Scientist
guardian

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Techno-optimist narrative

Gene therapy is entering its most transformative era yet, with AI-designed proteins, precise CRISPR editing and approved treatments for retinal disorders, spinal muscular atrophy and blood cancers proving the science works. Viral and non-viral delivery systems keep improving in safety and efficiency, expanding the range of treatable diseases fast. Market-driven biotech innovation is accelerating cures at a pace no government program could match.

International Journal Pharmaceutical Sciences

Mgoes on X

Techno-skeptic narrative

Gene therapy's promise is being strangled by broken economics and political neglect. Per-patient costs can run into seven figures, and companies like Prime Medicine are already halting work on successful treatments because the business model doesn't hold up. Only a publicly funded health system treating gene therapy like dialysis or transplants — a collective service, not a market commodity — can turn lab breakthroughs into medicine for everyone.